Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a faster, Higher-Power heart ablation beat the standard for AFib?

NCT ID NCT07728539

Disease control Sponsor: Bakulev Scientific Center of Cardiovascular Surgery Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial tests whether a new high-power short-duration radiofrequency ablation technique (90 watts for 4 seconds) is safer and more effective than the standard low-power approach (35 watts for 10-15 seconds) for treating atrial fibrillation. The study includes adults with paroxysmal or persistent AFib who have not responded to medication. Researchers will track AFib recurrence and complications over 12 months to see which method offers better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiofrequency ablation using high-power short-duration (90 W, 4 s) or standard low-power (35 W, 10-15 s) settings
What this could lead to
If the high-power short-duration approach proves safer and more effective, it could become a new standard for treating atrial fibrillation, reducing recurrence and complications.
What could go wrong
This is a single-center trial with 196 participants, so results may not apply broadly. The high-power technique carries risks like esophageal injury, and it may not outperform the standard method.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 196 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age over 18 years old; * Atrial fibrillation resistant to antiarrhythmic therapy; * Paroxysmal form of atrial fibrillation; * Persistent form of atrial fibrillation; * The patient's consent to participate in the study. Exclusion Criteria: Exclusion Criteria: * Age under 18 and over 80 years old; * The presence of another cardiac pathology requiring surgical treatment; * Congenital heart defects; * Previous "open" cardiac surgery; * Bone marrow diseases; * Pathology of the blood coagulation system; * The left ventricular ejection fraction is less than 40%; * Moderate to severe renal insufficiency (creatinine clearance \<50 ml/min); * Drug-resistant hypertension (despite hypotensive therapy); * Organically altered mitral valve; * There are reasons to assume that the patient will not show up for subsequent visits (control points of the study) for various reasons; * The patient's participation in another clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute cerebrovascular accident are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation Death stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute cerebrovascular accident Atrial fibrillation (AF) Atrial fibrillation recurrent Death Stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bakulev National Medical Research Center for Cardiovascular Surgery

    RECRUITING

    Moscow, 121552, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.